What Tarom Innovative Technologies does

Tarom Innovative Technologies Ltd. is an Israeli life-sciences venture studio that creates and grows breakthrough healthcare innovations through a diversified portfolio of six pre-clinical and early-clinical therapeutic and diagnostic programs. The pipeline spans oncology (MetaboCure/Nuforal for cancer cachexia via mRNA/LNP, Remission for solid-tumor CAR-T, Oncombat for small cell lung cancer), infectious disease (Pepticore/PheLiz combinatorial peptide antibiotic for antimicrobial resistance), neurology (Neuropredix AI-driven MS prognostic score), and early cancer detection (Clonal TCR-based blood test). The company serves unmet medical needs in advanced cancer patients, individuals with resistant infections, and patients requiring precision prognostic tools, operating from Petah Tikva, Israel.

The company is a subsidiary of Tarom Applied Technologies Ltd., a clinical diagnostics and life sciences distribution business founded in 1989, and operates alongside sister entity Tarom Digital Health, which delivers medical-grade digital health solutions to healthcare organizations in Israel and select growth markets. Competitive positioning rests on multiple proprietary technology platforms across distinct modalities (mRNA/LNP, CAR-T, peptide-drug conjugates, AI-driven diagnostics), collaborations with leading Israeli research institutions including Rambam Medical Center, Ichilov-Sourasky Medical Center, and Weizmann Institute of Science, and a leadership team with deep biopharmaceutical R&D experience.

As a pre-commercial venture studio, Tarom Innovative Technologies does not currently generate product revenue. Its operating model centers on advancing pipeline programs through preclinical and clinical milestones with the objective of maturing each venture into an independent biotechnology company. The model is supported by non-dilutive funding sources such as Israel Innovation Authority grants, and leverages the Tarom Group's commercial infrastructure for distribution reach and institutional relationships.

Name

Tarom Innovative Technologies

Legal name

Tarom Innovative Technologies Ltd.

Website

https://tarominnovative.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Tarom Innovative Technologies is an Israeli life-sciences venture studio that builds and incubates breakthrough therapeutic and diagnostic platforms across oncology, infectious disease, and neurology, with six active R&D programs targeting cancer cachexia, solid tumors, antimicrobial resistance, and AI-driven prognostics.

Ownership category

akta.pro rank

Product category

Life-Sciences Venture Studio / Biotech Incubation

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Life-sciences venture studio
• Biotech incubation
• Therapeutic pipeline
• AI diagnostics development
• Healthcare innovation

Headquarters

HQ city

Petah Tiqva

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Marketing channels3 records

Core offering

Tarom Innovative Technologies is a life-sciences venture studio that identifies, invests in, incubates, and develops breakthrough healthcare innovations across therapeutics and diagnostics. The company builds a diversified pipeline of pre-clinical and early-stage assets spanning mRNA/LNP therapeutics (MetaboCure), engineered CAR-T cell therapies (Remission), peptide-drug conjugates (Oncombat), antimicrobial peptide cocktails (Pepticore), AI-driven prognostic diagnostics (Neuropredix), and TCR-based blood tests for early cancer detection (Clonal). Operating under the Tarom Group, it provides end-to-end support including funding, hands-on management, scientific and clinical development, and business development to mature each project into an independent biotech venture.

Product overview

Tarom Innovative Technologies is a life-sciences Venture Studio that creates and grows breakthrough healthcare innovations. The company operates a diversified portfolio including six therapeutic and diagnostic pipeline products: MetaboCure (mRNA/LNP-based cachexia treatment with lead candidate Nuforal for pancreatic cancer), Remission (CAR-T cell therapy for solid tumors starting with ovarian cancer), Pepticore (combinatorial peptide antibiotic PheLiz for resistant infections), Oncombat (peptide-drug conjugates for small cell lung cancer), Neuropredix (AI-driven MS prognostic tool), and Clonal (TCR-based early cancer detection). The portfolio is complemented by sister companies including Tarom Applied Technologies (clinical diagnostics distributor founded 1989) and Tarom Digital Health (medical-grade digital health solutions). The company also holds portfolio interests in MammaPrint (genomic breast cancer recurrence test).

Differentiator

Problem solved

Functional benefit

Brands

• MetaboCure: Breakthrough treatment for cancer cachexia using mRNA/LNP technology. First indication: pancreatic cancer cachexia. Product: Nuforal™.
• Remission
• Pepticore
• Oncombat
• Neuropredix
• Clonal

Products and services

• MetaboCure (Nuforal)

Quantifiable outcome

• Cancer cachexia affects up to 80% of advanced cancer patients
• +3 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• Rambam Medical Center (Haifa)coreStrategic or Co-development PartnerCollaborating research institution for Remission project - CAR-T cell therapy for solid tumors. Team from Rambam contributes to development of next-generation immunotherapy targeting ovarian cancer.
• Ichilov-Sourasky Medical Center (Tel-Aviv)coreStrategic or Co-development PartnerCollaborating research institution for Remission project. Contributing scientific expertise and clinical research capabilities to CAR-T cell therapy development for solid tumors.
• Weizmann Institute of Science (Rehovot)coreStrategic or Co-development PartnerFoundational research partner for Remission project. Provides scientific leadership and research infrastructure for developing innovative CAR-T treatment specific to ovarian cancer.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• CureVac: mRNA therapeutics company developing vaccines and oncology therapeutics. Comparable modality to Tarom's MetaboCure project and similar bet on mRNA as a multi-indication platform.
• BioNTech: Global mRNA/LNP therapeutics leader. Directly comparable to Tarom's MetaboCure project (Nuforal) which uses mRNA/LNP to restore HNF4a; both companies apply mRNA platforms to indications beyond COVID-19 vaccines.
• PeptiDream: Japanese peptide-drug conjugate discovery platform serving multiple therapeutic areas. Comparable to Tarom's Oncombat (peptide-drug conjugates) and Pepticore (combinatorial peptide antibiotics) in peptide-based drug discovery.
• Moderna: Leading mRNA therapeutics company with broad pipeline across oncology, rare diseases, and infectious diseases. Comparable modality to Tarom's mRNA/LNP-based MetaboCure and similar multi-indication strategy.
• Allogene Therapeutics: Clinical-stage CAR-T cell therapy company pursuing both hematologic and solid tumor indications. Most directly comparable to Tarom's Remission project, which also engineers CAR-T cells with novel functionality for solid tumor infiltration.
• Cellectis: Gene-edited CAR-T cell therapy company with proprietary allogeneic platform. Comparable to Tarom's Remission project for engineered immune cell functionality and novel method architecture in solid tumor CAR-T.
• BioLineRx: Israeli clinical-stage biotech developing multiple therapeutic candidates across oncology and rare diseases. Comparable as a fellow Israeli biotech with a multi-asset pipeline strategy and similar early-stage risk profile.

Emerging players

• Iterative Scopes: Earlier-stage AI-driven diagnostics company applying machine learning to medical imaging. Comparable to Tarom's Neuropredix and Clonal projects in the AI/machine learning diagnostic category.

Broad incumbents

• Flagship Pioneering: Biotech venture studio that originates and builds multiple platform companies (e.g., Moderna). Directly comparable business model to Tarom's venture studio model of creating and growing multiple breakthrough healthcare companies.
• BridgeBio Pharma: Multi-asset biotech builder with a hub-and-spoke model for spinning out therapeutic programs. Comparable to Tarom's venture studio approach of building multiple breakthrough healthcare programs under one umbrella.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Customer concentration

• LinkedInlinkedin.com/company/tarom-innovative-technologies-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tarom Innovative Technologies